Results summaries for study participants

We work with regulators to help share clinical trial information with our participants.

As part of our patient focused drug development here at AbbVie, we strive to provide summary information about completed trials in an easy and understandable manner while upholding our commitments to trade associations principles and preparedness for the upcoming European Union (EU) Clinical Trials Regulation requirements.

A summary of clinical trial results for laypersons, referred to as a lay summary of results or plain language summary (PLS), is a brief description of the clinical trial results in everyday language that is understandable to people who do not have a medical or scientific background. In 2019, AbbVie publicly disclosed Plain Language Summaries (PLS) of results for phase 2-4 clinical trials completed in 2018 for already approved products and or indications. In 2020, the set of studies in scope includes interventional trials completed in 2019.

See below for available summaries:

Virology

Study ID/Title Condition Description
M15-592
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat Asian adult patients with long-lasting hepatitis C genotype 1 to 6 infection without liver cirrhosis (scarring of the liver) Hepatitis C virus

Trial dates:
Oct 2017 – Feb 2019

Last modified:
Dec 2019

Available languages:
ChineseEnglish,
Korean

M15-593
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat Asian adult patients with long-lasting hepatitis C genotype 1 to 6 infection with compensated liver cirrhosis (scarring of the liver while the liver is still able to function) Hepatitis C virus

Trial dates:
Sept 2017 – Feb 2019

Last modified:
Jan 2020

Available languages:
ChineseEnglish,
Korean

M16-126
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis-C genotype 5 or 6 infection Hepatitis C virus

Trial dates:
Jan 2017 – Aug 2018

Last modified:
Sep 2019

Available languages:
EnglishFrench,
French Canadian,
Vietnamese

M16-127
A study to learn how well and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis-C infection and kidney damage
Hepatitis C virus

Trial dates:
Mar 2017 – Jun 2018

Last modified:
May 2019

Available languages:
EnglishGerman,
ItalianKorean,
PolishSpanish

M16-133    
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis C infection who had never been treated before and had no liver cirrhosis (scarring of the liver) based on the result of the APRI blood test Hepatitis C virus

Trial dates:
Aug 2017 – Aug 2018

Last modified:
Sep 2019

Available languages:
BulgarianEnglish,
GermanPolish,
RussianSpanish

M16-135    
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis C genotypes 1–6 infection with scarring of the liver who have not been treated before Hepatitis C virus

Trial dates:
Apr 2017 – Nov 2019

Last modified:
Oct 2020

Available languages:
EnglishBulgarian,
CzechRomanian,
RussianSpanish

M13-576    
A study to learn if the hepatitis C virus remains undetectable in adult patients long after treatment with glecaprevir and/or pibrentasvir Hepatitis C virus

Trial dates:
Jun 2015 - Oct 2019

Last modified:
Oct 2020

Available languages:
EnglishDutch,
SpanishGerman

 

 

Immunology

Study ID/Title Condition Description
M11-290
A study to learn how effective and safe a medicine called adalimumab works to treat children with moderate to severe ulcerative colitis Ulcerative colitis

Trial dates:
Oct 2014 - Feb 2020

Last modified:
Mar 2021

Available languages:
EnglishSpanish,
DutchSlovakian,
JapanesePolish

M11-327
A study to learn how well and safe long-term use of a medicine called adalimumab works to treat adult patients with non-infectious intermediate uveitis, posterior uveitis, or panuveitis Uveitis

Trial dates:
Dec 2010 – May 2018

Last modified:
Jul 2019

Available languages:
EnglishGerman,
ItalianJapanese
PolishSpanish

M14-033    
A study to learn how effective and safe higher doses of the study drug adalimumab is for patients with ulcerative colitis Ulcerative colitis

Trial dates:
Mar 2014 - Nov 2019

Last modified:
Oct 2020

Available languages:
EnglishDutch,
ItalianSpanish
JapanesePolish
Ukrainian

M14-115
A study to learn how effective and safe a medicine containing the study drug adalimumab works to treat patients with moderate to severe Crohn’s disease


Crohn's Disease

Trial dates:
May 2014 - Jan 2020

Last modified:
Feb 2021

Available languages:
EnglishPolish
DutchUkrainian,
HebrewCzech

M14-496
A study to learn how effective and safe adalimumab is compared to methotrexate in the treatment of adult patients with psoriatic arthritis Psoriatic arthritis

Trial dates:
Aug 2016 - Mar 2020

Last modified:
Mar 2021

Available languages:
EnglishPolish,
PortugueseCzech,
SpanishBulgarian

M14-500
A study to learn if clinical disease activity measured by Magnetic Resonance Imaging (MRI) helped predict flares in adult patients with rheumatoid arthritis in remission who were being treated with dose-tapered adalimumab
Rheumatoid arthritis

Trial dates:
Jan 2015 – Aug 2018

Last modified:
Oct 2019

Available languages:
EnglishGerman
ItalianSpanish

M15-574
A study to learn how effective and safe the study drug adalimumab is for patients with hidradenitis suppurativa Hidradenitis suppurativa

Trial dates:
Jul 2016 - Oct 2019

Last modified:
Aug 2020

Available languages:
EnglishDutch
GermanGreek
SpanishTurkish

M15-989
A study to learn how safe a medicine containing the study drug risankizumab is for patients with moderate to severe Crohn's disease Crohn's Disease

Trial dates:
Sep 2015 – Jun 2019

Last modified:
May 2020

Available languages:
EnglishDutch
KoreanSpanish
GermanPolish

M15-992 
A study to learn how effective and safe a medicine containing the study drug risankizumab is compared to placebo (no medicine) to treat adult patients with moderate to severe long-lasting plaque psoriasis after initial treatment, withdrawal, relapse, and re-treatment Psoriasis

Trial dates:
Feb 2016 – Jul 2018

Last modified:
Sep 2019

Available languages:
EnglishFrench
French Canadian
GermanJapanese
Korean

M16-004 
A study to learn how effective and safe a medicine containing the study drug risankizumab works compared to placebo (no medicine) to treat adult Japanese patients with moderate to severe long-lasting plaque psoriasis Psoriasis

Trial dates:
Dec 2016 – Jun 2018

Last modified:
Aug 2019

Available languages:
EnglishJapanese

M16-009
A study to learn how effective and safe a medicine containing the study drug risankizumab works to treat adult patients with moderate to severe long-lasting plaque psoriasis

Psoriasis

Trial dates:
Nov 2014 – Sep 2018

Last modified:
Jul 2019

Available languages:
EnglishFrench
French Canadian,
German

M16-048
A study to learn how safe and effective a medicine containing the study drug upadacitinib works compared to placebo (no medicine) to treat adult patients with moderate to severe atopic dermatitis Atopic dermatitis

Trial dates:
Oct 2016 – Jan 2019

Last modified:
Apr 2020

Available languages:
EnglishFinnish
DutchJapanese
German

M16-063
A study to learn how effective and safe elsubrutinib taken by itself or in combination with upadacitinib works to treat adult patients with rheumatoid arthritis compared to placebo

Rheumatoid arthritis

Trial dates:
Oct 2018 - Mar 2020

Last modified:
Mar 2021

Available languages:
EnglishCzech,
DutchHungarian,
PolishSpanish

M16-176
A study to learn how effective and safe a medicine containing the study drug risankizumab is compared to placebo (no medicine) to treat adult patients with moderate to severe plaque psoriasis


Psoriasis

Trial dates:
Jul 2018 - Dec 2019

Last modified:
Jan 2021

Available languages:
EnglishRussian

M16-178
A study to learn how effective and safe a medicine containing the study drug risankizumab works compared to the study drug FUMADERM® to treat adult patients with moderate to severe plaque psoriasis Psoriasis

Trial dates:
Aug 2017 – Jul 2018

Last modified:
Jul 2019

Available languages:
EnglishGerman

M16-244  

 

A study to learn how safe and effective a medicine containing the study drug risankizumab is for adult patients with psoriatic arthritis Psoriatic arthritis

Trial dates:
Dec 2016 – Jul 2018

Last modified:
May 2020

Available languages:
EnglishCzech
FinnishJapanese
PolishSpanish

 

Oncology

Study ID/Title Condition Description
M11-089    
A study to learn how effective and safe a medicine containing veliparib is compared to placebo (no medicine) taken in combination with standard chemotherapy to treat adult patients with certain types of advanced lung cancer Lung cancer

Trial dates:
Apr 2014 - Nov 2019

Last modified:
Jul 2020

Available languages:
EnglishDutch
HungarianRussian
TurkishUkrainian

M16-289
A study to compare the efficacy and safety of the experimental study drug rovalpituzumab tesirine (Rova-T) to topotecan in patients with small cell lung cancer who progressed after chemotherapy



Lung cancer

Trial dates:
Apr 2017 - Feb 2020

Last modified:
Dec 2020

Available languages:

EnglishJapanese
KoreanDutch
French,  Spanish
Turkish

M16-298    
A study to learn the safety and effectiveness of rovalpituzumab tesirine (Rova-T) in patients who have advanced small cell lung cancer when Rova-T is used immediately after patients have completed taking chemotherapy Lung cancer

Trial dates:
Feb 2017 - Nov 2019

Last modified:
Nov 2020

Available languages:
EnglishDutch
JapaneseTurkish
SpanishRussian

M14-359
A study to learn how effective and safe a medicine containing veliparib in combination with paclitaxel and carboplatin is compared to study doctor’s choice of chemotherapy to treat adult patients with a certain type of advanced lung cancer


Lung cancer

Trial dates:
Sep 2014 - Feb 2020

Last modified:
Dec 2020

Available languages:
EnglishDutch
HungarianJapanese
RussianSpanish
Turkish

M14-361
A study to learn how effective and safe a medicine containing veliparib works to treat adult patients with advanced small cell lung cancer in combination with carboplatin and etoposide


Lung cancer

Trial dates:
Oct 2014 - Apr 2019

Last modified:
Apr 2020

Available languages:
EnglishRussian
DutchHungarian
SpanishKorean

M14-483  
A study to learn how effective and safe depatuxizumab mafodotin alone and in combination with temozolomide works to treat patients with recurrent glioblastoma compared to lomustine or temozolomide


Glioblastoma

Trial dates:
Feb 2015 - Aug 2019

Last modified:
Dec 2020

Available languages:
EnglishDutch
FrenchItalian
KoreanSpanish

M16-534
A study to learn how to best manage eye side effects in patients treated with depatuxizumab mafodotin for glioblastoma


Glioblastoma

Trial dates:
Jul 2018 - Mar 2020

Last modified:
Feb 2021

Available languages:
EnglishGerman

 

Neuroscience

Study ID/Title Condition Description
M15-535  
A study to learn how effective and safe a medicine containing levodopa-carbidopa is compared to current standard patient medication to treat dyskinesia in adult patients with advanced idiopathic Parkinson's disease Parkinson's Disease

Trial dates:
Feb 2017 - Sep 2019

Last modified:
Jul 2020

Available languages:
EnglishItalian
FinnishSlovak
GreekSpanish

M15-562    
A study to learn how safe and effective a medicine containing tilavonemab is compared to placebo to treat adult patients with Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy

Trial dates:
Dec 2016 - Nov 2019

Last modified:
Oct 2020

Available languages:
EnglishItalian
FrenchJapanese
SpanishGerman

M15-563    
An extension study to learn how safe and effective a medicine containing tilavonemab is to treat Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy

Trial dates:
Jan 2018 - Dec 2019

Last modified:
Nov 2020

Available languages:
EnglishItalian